Orexin antagonists settle into routine insomnia care
Dual-orexin-receptor-antagonist therapy is normalising into routine insomnia prescribing as benzodiazepine-class avoidance hardens.
Insomnia therapy is moving away from benzodiazepine and Z-drug classes for chronic use, and orexin-receptor antagonists are establishing a defensible position. The commercial question is whether the class consolidates around the first two molecules or fragments as additional entrants arrive over the next 18 months.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
TreatmentPipelineSafety
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.